Since we did not collect the respective biomaterial from all our patients, we were unable to investigate and compare cytokine profiles and immune cell subtypes in sera and CSF in MS patients with and without NLRP3-, MEFV-, and TNFRSF1A low-penetrance variants. This evidence concerns the gene MEFV and myeloid sarcoma.